“Administering oxygen is a basic nursing treatment,” says Hendrickx. “With such a therapy, oxygen is pumped through nasal tube to provide a constant flow to the patient. If patients do not breathe in, or if they exhale or take off their oxygen masks, the oxygen is lost into the environment. Moreover, because of the constant supply of oxygen, patients quickly get dehydrated noses, nosebleeds and scabs. With our technology, however, oxygen is only administered when the patient inhales.”
The technology and accompanying devices, for which the entrepreneurs raised EUR 3.8 million in a first capital round from Flanders’ investment fund PMV in 2018, have been finalized for some time now. Around 3,000 O2Comfort devices are already in use in thirty hospitals, mainly in Flanders. Thanks to the new contract with German company Linde, the market for O2Comfort is bound to grow.